Leerink Swann Maintains an 'Outperform' on Medivation (MDVN); Number of Advantages Based on Labeling
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Brean Murray Carret & Co. Maintains a 'Buy' on Medivation (MDVN); Adjusting Numbers on Xtandi Approval
September 4, 2012 8:52 AM EDTBrean Murray Carret & Co. maintains a 'Buy' on Medivation (NASDAQ: MDVN) price target of $125.00 (from $105.00).
Analyst, MDVN's XTANDI (enzalutamide; MDV3100) was approved by the FDA on August 31 for patients with metastic castration-resistant prostate cancer who have previously received docetaxel, but we... More
Jefferies Reiterates a 'Buy' on Medivation (MDVN); Xtandi Approved Early
September 4, 2012 7:17 AM EDTJefferies reiterates a 'Buy' on Medivation (NASDAQ: MDVN) price target of $122.00 (from $113.00).
Analyst, Biren Amin, said, "Xtandi (enzalutamide) approval came ~3 months ahead of its November PDUFA date, and a slight positive on ~1 addl qtr of sales. The label was generally in-line... More
Medivation (MDVN) Up ~8% Following Halt for Xtandi Approval
August 31, 2012 4:01 PM EDTMedivation, Inc. (Nasdaq: MDVN) is now up 7.8 percent on the session after resumption.
Shares were up slightly before being halted for FDA approval of Xtandi for late stage prostate cancer.... More
Dendreon (DNDN) Hit After Medivation Wins FDA Approval for Prostate Cancer Drug
August 31, 2012 1:15 PM EDTDendreon Corp. (Nasdaq: DNDN) is seeing a little weakness here after the FDA approved Medivation (Nasdaq: MDVN) and Astellas XTANDI treatment for prostate cancer.
Shares of DNDN are down 1.6 percent.... More
FDA approves Medivation (MDVN) XTANDI for Prostate Cancer
August 31, 2012 1:11 PM EDTFDA approves Medivation (Nasdaq: MDVN) XTANDI treatment for prostate cancer (shares were halted)... More
